Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | NPM1 | P06748 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784640 | 0.90 | QDPR (0.63) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1781447 | 0.84 | QDPR (0.56) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12179659 | 0.84 | QDPR (0.50) | QDPRFLT4PTK2 | |
| SCHEMBL18310126 | 0.81 | QDPR (0.66) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3316510 | 0.80 | QDPR (0.52) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16992037 | 0.80 | QDPR (0.64) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3743608 | 0.79 | MAPT (0.51) | QDPR | |
| SCHEMBL3503526 | 0.77 | EGFR (0.61) | EGFRALK | |
| SCHEMBL18764021 | 0.76 | EGFR (0.49) | QDPRPDE4BCCR5EGFR | |
| SCHEMBL3731033 | 0.76 | SLC18A3 (0.66) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | QDPR 3069/4885PDE4B 2391/4885PDE4A 1972/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | QDPR 3069/4885PDE4B 2391/4885PDE4A 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.